Thus, to investigate the anti-cancer effect of OXY as a PI3K/AKT signaling blocker and assess the possibility of its use in clinical practice, we conducted an in vitro study on ovarian cancer cell lines (SKOV3 and TOV21G). Here, AKT1 is linked to ovarian cancer.